Clinical trials: Fat; Liver
Liver Diseases
Effect of Non-alcoholic Fatty Liver Disease on Kidney Functions
Non-alcoholic fatty liver disease is the most common cause of chronic liver disease worldwide. It is defined as the accumulation of fat (>5%) in the liver cells in the absence of excessive alcohol intake or other causes of liver…
- Trial name
- NCT03172650
- Testing
- glomerular filtration rate
- Where
- Egypt
- Volunteers
- 120 people
- Sponsor
- Assiut University
Nonalcoholic Fatty Liver Disease
Observational Study About Patients Diagnosed With NAFLD
Nonalcoholic fatty liver disease (NAFLD) is the most common condition affecting the liver, owing to its association with obesity and the metabolic syndrome.
- Trial name
- NCT05625750
- Where
- China
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Xiangya Hospital of Central South University
Hepatitis B, Chronic, Hepatic Steatosis
Aerobic Exercise Training in Patients With Chronic Hepatitis B and Hepatic Steatosis
This study is a randomised, controlled, unblinded, clinical intervention trial consisting of 12 weeks of aerobic exercise training.
- Trial name
- FitLiver (NCT05265026)
- Testing
- High Intensity Interval Training
- Where
- Denmark
- Volunteers
- 19 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Non-alcoholic Fatty Liver Disease, Liver Fibrosis
Clinical Trials Using HepatoKeeper Herbal Essentials to Treat Non-alcoholic Fatty Liver Disease and Metabolic Factors
Nonalcoholic fatty liver disease (NAFLD) is the most common liver disease globally, with an estimated prevalence of approximately 15 to 30%.
- Conditions
- Non-alcoholic Fatty Liver Disease, Liver Fibrosis, Liver Injury
- Trial name
- NCT06244550
- Testing
- Ganwei, Metformin
- Where
- Taiwan
- Volunteers
- 60 people
- Sponsor
- Taipei City Hospital
Psoriasis, Nonalcoholic Fatty Liver Disease
A Case Control Study Evaluating the Prevalence of Non-Alcoholic Fatty Liver Disease Among Patients With Psoriasis
Main objectives 1. Establish the association of psoriasis and the presence of NAFLD in the patients with psoriasis attending dermatologic clinic center. Secondary objective 1.
- Trial name
- NCT00930384
- Where
- United States
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- George Washington University
Non-Alcoholic Fatty Liver Disease, Non Alcoholic Steatohepatitis
Fecal Microbiota Transplantation for the Treatment of Non-Alcoholic Steatohepatitis
Human microbiota is the set of microorganisms that, in a symbiotic way, coexist and develop in the different surfaces (skin and mucous membranes) of the human body.
- Trial name
- FMT-NASH (NCT03803540)
- Testing
- Fecal Microbiota Transplantation
- Where
- Spain
- Volunteers
- 15 people
- Sponsor
- Puerta de Hierro University Hospital
NAFLD (Nonalcoholic Fatty Liver Disease)
Integrating Metabolic and Vascular Sensors to Monitor Cardiometabolic Disorders After Nutrition Interventions
It is a 12-week study. The participants will follow three different diets, and during each diet period, and the participants will wear our device, and blood samples will be collected.
- Trial name
- NCT06932289
- Testing
- Mediterranean diet (MED), high-fat/low carb diet (HF/LC), and low-fat diet (LF), The integrated sweat sensor and vascular sensor (wearable), continuous glucose monitor (CGM)
- Where
- United States
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- VA Greater Los Angeles Healthcare System
NAFLD - Nonalcoholic Fatty Liver Disease
Losartan for the Treatment of Pediatric NAFLD
A multicenter, randomized, double masked, placebo-controlled, parallel treatment groups phase 2 trial of losartan for pediatric nonalcoholic fatty liver disease (NAFLD).
- Trial name
- STOP-NAFLD (NCT03467217)
- Testing
- Losartan potassium
- Where
- 10 sites in United States
- Volunteers
- 83 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Non-Alcoholic Fatty Liver Disease, Non Insulin Dependent Diabetes
A Prospective, Randomized, Open Label Trial of Two Doses of Oral Betaine
Betaine (trimethyglycine) is a food supplement that is approved for sale in the United States without a prescription. In this study, betaine will be provided to patients as a powder that can be mixed with aqueous solutions and…
- Conditions
- Non-Alcoholic Fatty Liver Disease, Non Insulin Dependent Diabetes, ALT
- Trial name
- NCT03073343
- Testing
- Betaine (trimethyglycine)
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Southern California Institute for Research and Education
Non-Alcoholic Fatty Liver Disease, Hepatitis B
A Prospective Study of HBV Immunity and HBV Vaccination in Patients With NAFLD in Canada
(1) Due to missed childhood vaccination programs, the majority of adult patients with NAFLD in Canada do not have immunity to hepatitis B.
- Conditions
- Non-Alcoholic Fatty Liver Disease, Hepatitis B, Vaccine Reaction
- Trial name
- NCT02985450
- Testing
- Engerix-B
- Where
- Canada
- Volunteers
- 82 people
- Sponsor
- University of Calgary
Hepatic Steatosis, Overweight and Obesity
Implementation of the Fatty Liver Index in Primary Care
This trial aims to evaluate the impact on cardiovascular risk control in individuals in risk of being affected by hepatic steatosis through the implementation of a screening test (Fatty Liver Index) in Primary Care.
- Trial name
- FLI-AP (NCT06363617)
- Testing
- FLI
- Where
- Spain
- Volunteers
- 434 people
- Sponsor
- Consorci Sanitari de l'Alt Penedès i Garraf
NAFLD
Polyunsaturated Fatty Acids in Patients With NAFLD.
Patients with metabolic syndrome and Nonalcoholic fatty liver disease (NAFLD) will be randomly allocated for the treatment with n-3 PUFA (3.6 g/day) or placebo for 12 months.
- Trial name
- NCT02647294
- Testing
- Maxicor
- Where
- Czechia
- Volunteers
- 60 people
- Sponsor
- General University Hospital, Prague
Non-Alcoholic Fatty Liver Disease, Cardiovascular Diseases
EndoNAFLD: Relationship Between Fatty Liver Disease and Cardiovascular Diseases
Management of risk factors is the primary approach to prevent cardiovascular disease (CVD). In this regard the accurate scoring of disease risk is fundamental.
- Trial name
- Endo-NAFLD (NCT06392828)
- Where
- 4 sites in Spain
- Volunteers
- 63 people
- Sponsor
- IMDEA Food
Non-Alcoholic Fatty Liver Disease, Cardiovascular Diseases
NAFLD Primary Care
Non-alcoholic fatty liver disease (NAFLD) is with 25% the most prevalent liver disorder in Western society and is associated with overweight, obesity, metabolic syndrome (MetS), type 2 diabetes mellitus (T2DM), cardiovascular…
- Conditions
- Non-Alcoholic Fatty Liver Disease, Cardiovascular Diseases, Type2 Diabetes, Metabolic Syndrome
- Trial name
- NCT04918732
- Testing
- FibroScan
- Where
- Netherlands
- Volunteers
- 1,470 people
- Sponsor
- Maastricht University
Non-alcoholic Steatohepatitis (NASH)
Treatment of Non-alcoholic Steatohepatitis (NASH) Patients With Vitamin D
Test the efficacy of vitamin D to improve non-alcoholic steatohepatitis with regard to biochemical and histological parameters. Trial with medicinal product
- Trial name
- NCT01571063
- Testing
- Vitamin D3
- Where
- 2 sites in Switzerland
- Volunteers
- 22 people
- Sponsor
- University of Zurich
NAFLD
Use of Shear Wave Elastography to Assess Non-alcoholic Fatty Liver Disease (NAFLD)
The aim of this study is to test a non-invasive imaging technique to reliably diagnose NAFLD in children and adolescents with obesity and assess the degree of fibrosis.
- Trial name
- NAFLD (NCT03587298)
- Testing
- Real-Time (Supersonic)- 2D shear wave elastography (rt-SWE)
- Where
- Germany
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- RWTH Aachen University
Nonalcoholic Fatty Liver Disease (NAFLD), Nonalcoholic Steatohepatitis (NASH)
The Farnesoid X Receptor (FXR) Ligand Obeticholic Acid in NASH Treatment Trial(FLINT)
Administration of the farnesoid X receptor (FXR) ligand obeticholic acid (OCA) for 72 weeks to subjects with biopsy evidence of nonalcoholic steatohepatitis (NASH) will result in improvement in their liver disease as measured by…
- Trial name
- FLINT (NCT01265498)
- Testing
- obeticholic acid
- Where
- 9 sites in United States
- Volunteers
- 283 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Fatty Liver, Fatty Liver, Alcoholic
Fatty Liver Disease Collaborative Research in China
A multi-center, prospective cohort study on the natural history of fatty liver disease in China
- Conditions
- Fatty Liver, Fatty Liver, Alcoholic, Non-alcoholic Fatty Liver Disease
- Trial name
- FLDCR (NCT02391168)
- Where
- 6 sites in China
- Volunteers
- 3,000 people
- Sponsor
- Fatty Liver and Alcoholic Liver Disease Study Group, China
Cardiovascular Diseases, Metabolic Syndrome
Redirecting Immune, Lipid and Metabolic Drivers of Early Cardiovascular Disease: The RESET Cohort Study
Project RESET is a Singapore National Medical Research Council Large Collaborative Grant funded program that brings together a nationwide community of cardiovascular, metabolic, and digital health researchers, as well as…
- Conditions
- Cardiovascular Diseases, Metabolic Syndrome, Non-Alcoholic Fatty Liver Disease
- Trial name
- RESET (NCT06211868)
- Testing
- Digital wearable and AI-human symbiotic lifestyle intervention
- Where
- Singapore
- Volunteers
- 3,000 people
- Sponsor
- National University Hospital, Singapore
Nonalcoholic Steatohepatitis
Efficacy and Safety of Viusid in Patients With Nonalcoholic Steatohepatitis
The purpose of the study is to evaluate whether Viusid, a nutritional supplement, in combination with diet and exercise improve the histological results (steatosis, necro-inflammatory activity and fibrosis) in comparison with…
- Trial name
- NCT00509418
- Testing
- Viusid, Hypocaloric Diet with controlled exercise
- Where
- Cuba
- Volunteers
- 60 people
- Sponsor
- Catalysis SL
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.